ARS Pharmaceuticals Names New CEO as Founder Steps Down After Decade
Event summary
- Richard Lowenthal, co-founder and CEO of ARS Pharmaceuticals, stepped down on July 6, 2026 after more than a decade of leadership.
- Donn Casale, former President, was appointed as the new CEO and Director effective July 7, 2026.
- Casale brings over 25 years of biopharmaceutical experience, including scaling Dynavax's HEPLISAV-B® to $300M in revenue before its $2.2B acquisition by Sanofi.
The big picture
The leadership transition at ARS Pharmaceuticals comes as the company seeks to solidify neffy's position in the competitive anaphylaxis treatment market. With only a fraction of at-risk patients consistently carrying epinephrine auto-injectors, Casale’s experience in scaling consumer-driven healthcare products could be pivotal. The move underscores the biopharmaceutical industry’s focus on operational and financial acumen to drive commercial success.
What we're watching
- Execution Risk
- Whether Casale can sustain the growth momentum of neffy, given its market penetration challenges.
- Market Dynamics
- The pace at which ARS Pharmaceuticals expands neffy's reach in large, consumer-driven healthcare markets.
- Strategic Shifts
- How Casale’s commercial track record will influence ARS Pharma’s long-term value creation strategy.